AKT1 and prostate cancer: SOX2 has been demonstrated to enhance the resistance of prostate cancer cells to paclitaxel through the PI3K/Akt signaling pathway, promote cellular proliferation, and display anti-apoptotic characteristics, thereby facilitating the emergence of hormone-refractory prostate cancer [82].